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Abstract
Background: Hypoxia induces activation of the HIF-1 pathway and is an essential characteristic of malignant
gliomas. Hypoxia has been linked to tumor progression, therapy resistance and poor prognosis. However, little is
known about the impact of HIF-1a inhibition on radioresistance of malignant glioma.
Methods: In this study, we investigated the effects of the inhibition of HIF-1a on cell survival and radiosensitivity
in U251MG and U343MG glioma cells, using two different strategies. HIF-1a inhibition was achieved by siRNA
targeting of HIF-1a or via chetomin, a disruptor of interactions between HIF-1a and p300. The inhibition of the
HIF-1 pathway was monitored by quantitative real-time PCR and Western blot analyses of the expression levels of
HIF-1a and CA9. CA9 expression was investigated as a potential indicator of the efficacy of HIF-1 inhibition and the
resulting radiosensitivity of malignant glioma cell lines was determined by clonogenic assay after irradiation under
normoxic (2-10 Gy) or hypoxic (2-15 Gy) conditions.
Results: Although siRNA and chetomin show distinct modes of action, both attenuated the hypoxia-induced
radioresistance of malignant glioma cell lines U251MG (DMF10: 1.35 and 1.18) and U343MG (DMF10: 1.78 and 1.48).
However, siRNA and chetomin showed diverse effects on radiosensitivity under normoxic conditions in U251MG
(DMF10: 0.86 and 1.35) and U343MG (DMF10: 1.33 and 1.02) cells.
Conclusions: Results from this in vitro study suggest that inhibition of HIF-1a is a promising strategy to sensitize
human malignant gliomas to radiotherapy and that CA9 could serve as an indicator of effective HIF-1-related
radiosensitization.
Background
Malignant gliomas are tumors of the central nervous
system originating from glial cells or their progenitors.
According to the WHO classification, malignant gliomas
are distributed in grade-III and grade-IV tumors [1,2].
Histologically characterized as pleomorphic, infiltrative
tumors with microvascular proliferation and high mito-
tic rates, these cells show poor response to treatment
[3]. Hence, patients with gliomas have a mean life
expectancy of approximately one year in clinical trials,
despite surgery, chemo- and radiotherapy [4]. With
increasing malignancy, gliomas exhibit intratumoral
hypoxia [5], which has been associated with poor
responses to radio- or chemotherapy [6,7]. The tran-
scription factor hypoxia inducible factor-1 (HIF-1), a
dimer of HIF-1a and HIF-1b, is a critical mediator of
the response to hypoxia. HIF-1 governs cellular adaption
to oxygen deficiency by regulating tumor-relevant genes
involved in energy metabolism, angiogenesis, cell prolif-
eration and apoptosis [8-10]. Overexpression of HIF-1a
promotes tumor growth, whereas the loss of HIF-1a
activity dramatically decreases tumor growth, vasculari-
zation and energy metabolism [11]. Suppression of HIF-
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reported to reduce the survival of glioblastoma cells and
accelerate p53-independent apoptosis [12]. In addition,
knockdown of HIF-1a by RNA interference attenuates
human glioma cell growth in vivo [13]. Furthermore,
downregulation of HIF-1a by siRNA increased the sen-
sitivity of human brain glioma cells to doxorubicin and
etoposide [14].
HIF-1 activity can also be inhibited by chetomin
(CTM), an epidithiodiketopiperazine metabolite of the
fungal species Chaetomium [15]. Treatment with CTM
attenuates hypoxia-inducibleg e n ee x p r e s s i o nv i ar e d u c -
tion of the HIF-1a/p300 complex. At the molecular level,
CTM disrupts the interactions of the C-terminal transac-
tivation domain (TADC) of HIF-1a with the CH1
domain of p300, a transcriptional coactivator [15]. Pre-
vious studies have revealed that HIF-1a inhibition by
CTM significantly reduced CA9 and VEGF mRNA
expression and enhances radiation response under
severely hypoxic conditions in human HT 1080 cells [16].
In the present study, we analyzed the inhibitory effects
of two alternative HIF-1 targeting strategies, HIF-1a-
siRNA and CTM, on HIF-1a expression and that of its
target gene carbonic anhydrase 9 (CA9) in human
malignant glioma cells. Further, we investigated whether
targeting HIF-1a affects the hypoxia-induced radioresis-
tance in these tumor cells.
Methods
Cell Culture Conditions and Treatments
Early-passage human glioma cell lines U251MG and
U343MG (American Type Culture Collection) were
grown in RPMI 1640 medium (Lonza, Walkersville, MD,
USA) containing 10% fetal bovine serum, 1% sodium
pyruvate, 185 U/ml penicillin and 185 μg/ml streptomycin
at 37°C in a humidified atmosphere containing 3% CO2.
Gene silencing by small interfering RNA (siRNA) was
carried out by transfection using HIF-1a-directed or
control (Luciferase GL2) double-stranded RNA oligonu-
cleotides. HIF-1a and Luciferase (Lu) siRNA were
synthesized by Eurofins MWG Operon (Ebersberg,
Germany). The target sequences are depicted in addi-
tional file 1: “siRNA Target Sequences”. For siRNA
experiments, cells (1.5 × 10
5) were seeded in 12.5 cm
2
flasks 24 h before treatment with siRNA. At the time of
transfection, the confluency of the monolayer was 40-
50%. Different concentrations and (pre-) incubation
times of siRNA were analyzed in pilot experiments.
Transfection of 75 nM siRNA in U251MG and
U343MG cells was carried out using Interferin (poly-
plus-transfection Inc., NY, USA) following the manufac-
turer’s instructions. Cells were pre-treated with siRNA
for 4 h at 37°C under normoxic conditions. Then cells
were transferred for 20h to hypoxic conditions or main-
tained in a normoxic environment.
CTM (Alexis Biochemicals, Germany) was dissolved in
0.1% dimethyl sulfoxide (DMSO) for a 100 mM stock
solution. Cells (3 × 10
5) were seeded in 25 cm
2 flasks 24
hb e f o r et r e a t m e n tw i t h7 5n MC T M .A tt h et i m eo f
treatment, the confluency of the monolayer was 40-50%.
Different concentrations and (pre-) incubation times of
CTM were analyzed in pilot experiments. Cells were
treated with CTM or DMSO for 4 h at 37°C under nor-
moxic conditions. Then cells were transferred to
hypoxic conditions or maintained in a normoxic envir-
onment and incubated for 20 h.
Hypoxia and Irradiation
Hypoxia (<1% O2) was achieved using a gas generator
system as previously described [17]. Four hours after
siRNA transfection or incubation with CTM, the flasks
with the treated or untreated cells were transferred into
gas-proof plastic bags and cultured for 20 h under
hypoxic conditions.
Irradiation was delivered by a linear accelerator using
6 MV photons with adequate bolus material at a dose
rate of 200 MU/min. When normoxic conditions were
applied, the cells treated with siRNA or CTM were irra-
diated with a single dose of 2-10 Gy at room tempera-
ture. Cells under hypoxia treated with siRNA or CTM
were irradiated inside a plastic bag with a single dose of
2-15 Gy at room temperature. After irradiation, the cells
were incubated under normoxia or hypoxia at 37°C for
1 h before harvest for the clonogenic assay, RNA isola-
tion or protein isolation.
Clonogenic Assay and Radiosensitivity
Clonogenic Assay was performed as previously described
[17]. The surviving fractions were determined as ratios
of the plating efficiencies (PE = counted colonies/seeded
cells*100) of the irradiated cells to the non-irradiated
cells. The dose-modifying factor at a 10% survival level
(DMF10) was established to analyze the effects of siRNA
or CTM on the radiosensitivity of glioma cells (DMF10
= radiation dose untreated cells/radiation dose treated
cells). To fit the data a linear quadratic model lnS =
-(aD + bD
2) was applied, using origin 7.5.
Quantitative Real-Time PCR
Cells were washed twice with ice-cold phosphate buffered
saline (PBS) and harvested using a cell scraper. RNA was
isolated by using the RNeasy Mini Kit according to
the manufacturer’s instructions (QIAGEN, Hilden,
Germany). Reverse transcription was carried out as
described in additional file 2: “Reverse Transcription”.
Conditions for the quantitative real-time PCR (qRT-PCR)
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For normalization, hypoxanthine phosphoribosyltransfer-
ase (HPRT) was used as housekeeping gene. The primers
for the amplification were synthesized by TIB MOLBIOL
(Berlin, Germany), and their sequences are depicted in
additional file 4:” Primer Sequences”.
Western Blot Analysis
Cells were washed twice with ice-cold phosphate buf-
fered saline (PBS), harvested using a cell scraper and
lysed with RIPA-buffer (50 mM Tris-HCl, 200 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% TritonX-100,
0.25% deoxycholate, protease and phosphatase inhibi-
tors) 1 h after irradiation. The lysates were incubated on
ice for 20 min and centrifuged for 10 min at 13,000 rpm
at 4°C. The supernatants were collected and protein
concentrations were determined using the Bradford
method. Equivalent amounts of protein were resolved by
electrophoresis in 4-12% Bis-Tris Mini Gels (Invitrogen)
and then transferred to a PVDF membrane (Roth,
Karlsruhe, Germany) by tank-electroblotting (Bio-Rad,
München, Germany). Non-specific binding was blocked
by Tris buffered saline (TBS) containing 10% nonfat
powdered milk at room temperature for 1 h. The mem-
brane was incubated with the primary antibody at the
appropriate dilution in TBS-10% nonfat milk at 4°C
overnight. The membrane was then washed three times
with TBS and incubated with the appropriate horserad-
ish peroxidise-conjugated secondary antibody at room
temperature for 1 h. The protein-antibody complexes
were detected by enhanced chemiluminescence (ECL-
kit; Amersham, Freiburg, Germany). Details of the
utilized antibodies are described in additional file
5:"Antibodies”.
Statistical Analyses and Figures
Results are presented as means ± SD of n = 3 indepen-
dent experiments. Statistical analyses were performed by
Student’s t-test. A p-value < 0.05 was considered signifi-
cant. Results of figures (1;2;4) are expressed as a percen-
tage of control (75 nM control siRNA/75 nM DMSO
under normoxic conditions)
Results
Effects of HIF-1a-siRNA or CTM on HIF-1a and CA9 mRNA
Expression in U251MG and U343MG Cells
In both U251MG and U343MG cells, neither hypoxia
nor control siRNA or DMSO had an effect on HIF-1a
mRNA expression. Twenty-four hours after treatment,
the effect of the HIF-1a-siRNA or CTM on the HIF-1a
mRNA levels was analyzed under normoxic and hypoxic
conditions (Figure 1). Treatment of U251MG cells with
the HIF-1a-siRNA resulted in an inhibition of HIF-1a
mRNA by 58% (p=0.07, not significant) or 63%
(p = 0.005) under normoxic or hypoxic conditions,
respectively (Figure 1A). In U343MG cells, HIF-1a-
siRNA decreased the HIF-1a mRNA levels by 52% (p=
0.17, not significant) or 67% (p = 0.01) under normoxic
or hypoxic conditions, respectively (Figure 1B).
Exposure to CTM had no effect on HIF-1a mRNA
expression in U251MG cells (Figure 1C). However,
treatment of U343MG cells with CTM resulted in 67%
(p = 0.002) and 56% (p = 0.029) inhibition of HIF-1a
mRNA under normoxic and hypoxic conditions
(Figure 1D).
Inhibition of the HIF-1 activity was investigated by
monitoring the expression of the HIF-1a target gene car-
bonic anhydrase 9 (Figure 2). In both U251MG and
U343MG cells, hypoxia induced an increase in CA9
mRNA expression. Furthermore, neither control siRNA
nor DMSO had an effect on the CA9 mRNA expression.
Twenty-four hours after treatment, the effect of the
siRNA or CTM on the CA9 mRNA levels was analyzed
under normoxia and hypoxia (Figure 2). Effects of the
HIF-1a-siRNA and CTM on HIF-1a and CA9 mRNA
levels were compared to the respective control condition,
i.e., cells treated with control siRNA or the solvent
DMSO. Knockdown of HIF-1a by siRNA in U251MG
cells caused a 67% (p=0.14, not significant) or 68% (p =
0.06, not significant) decrease in the CA9 mRNA expres-
sion under normoxic or hypoxic conditions (Figure 2A).
A reduction in the CA9 mRNA expression by 57% (p =
0.12, not significant) or 38% (p = 0.01), accomplished by
HIF-1a knockdown, was also observed under normoxia
or hypoxia in U343MG cells (Figure 2B).
In U251MG cells, inhibition of HIF-1a activity in
response to CTM caused a 92% (p=0.002) or 51% (p=
0.18, not significant) decrease in CA9 mRNA expression
u n d e rn o r m o x i co rh y p o x i cc o nditions, respectively
(Figure 2C). In U343MG cells, treatment with CTM
caused 94% (p=0.04) and 87% (p=0.03) decrease of
the CA9 mRNA expression under normoxic or hypoxic
conditions (Figure 2D).
Effects of HIF-1a-siRNA or CTM on HIF-1a, CAIX and PARP
Protein Expression in U251MG and U343MG Cells
When we analyzed glioma cell lines, we found that,
under normoxic conditions, U251MG and U343MG
cells expressed small amounts of HIF-1a protein (Figure
3). Under hypoxia, HIF-1a protein levels were increased
in both U251MG and U343MG cells. Treatment with
control siRNA or DMSO did not affect HIF-1a protein
expression (Figure 3). Treatment of U251MG and
U343MG cells with the HIF-1a-siRNA strongly down-
regulated HIF-1a protein expression under normoxic
and hypoxic conditions (Figure 3A and 3B).
Exposure to CTM resulted in an increase of HIF-1a
protein expression under normoxic and hypoxic
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U251MG cells, the U343MG cells showed decreased levels
of HIF-1a protein in response to CTM (Figure 3D).
The CAIX protein is expressed in both U251MG and
U343MG cells under normoxic conditions. In response
to hypoxia, CAIX protein levels were substantially
increased in both cell lines (Figure 3). HIF-1a knock-
down strongly decreased CAIX protein expression in
both U251MG and U343MG cells, irrespective of
whether cells were grown under normoxic or hypoxic
conditions (Figure 3A and 3B).
In U251MG cells, inhibition of the HIF-1a transcrip-
tional activity by CTM down-regulated the normoxic
and hypoxic CAIX protein expression (Figure 3C).
Furthermore, CTM reduced the normoxic and hypoxic
CAIX protein expression in U343MG cells (Figure 3D).
Figure 1 Effects of HIF-1a-siRNA and CTM in U251MG and U343MG Cells: qRT-PCR of HIF-1a mRNA Levels. A (U251MG) and B
(U343MG), Silencing of normoxic and hypoxic HIF-1a mRNA levels using 75 nM HIF-1a-specific siRNA in comparison with 75 nM control siRNA
treated and untreated cells. C (U251MG), CTM slightly enhanced the HIF-1a mRNA expression under normoxic and hypoxic conditions. 75 nM
CTM in comparison with DMSO-treated and untreated cells. D (U343MG), CTM decreased the normoxic and hypoxic HIF-1a mRNA expression.
75 nM CTM in comparison with DMSO-treated and untreated cells.
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analysis qualitatively assess induction of apoptosis.
HIF-1a knockdown using siRNA did not affect the nor-
moxic expression of the large fragment of PARP, but
did cause PARP cleavage under hypoxic conditions in
U251MG cells (Figure 3A). In U343MG cells, HIF-1a
knockdown induced apoptosis under normoxic and
hypoxic conditions (Figure 3B).
Exposure to CTM caused induction of apoptosis
under normoxic and hypoxic conditions in U251MG
cells (Figure 3C). Furthermore, treatment with CTM
had no effect on apoptosis under normoxic conditions
but caused induction of apoptosis under hypoxic condi-
tions in U343MG cells (Figure 3D).
Effects of HIF-1a-siRNA or CTM on Clonogenic Survival
and Radiosensitivity
The clonogenic survival assay is a crucial endpoint read-
out that we used to determine the fraction of cells sur-
viving the treatment with the HIF-1a-siRNA or CTM
Figure 2 Effects of HIF-1a-siRNA and CTM in U251MG and U343MG Cells: qRT-PCR of CA9 mRNA Levels. A (U251MG) and B (U343MG),
Silencing of HIF-1a depleted the normoxic and hypoxic CA9 mRNA levels. CA9 mRNA levels using 75 nM HIF-1a-specific siRNA as compared to
75 nM control siRNA-treated and untreated cells. C (U251MG) and D (U343MG), CTM depleted the normoxic and hypoxic expression of CA9
mRNA. 75 nM CTM in comparison with DMSO-treated and untreated cells.
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siRNA or CTM and radiation (Figure 5).
Treatment with control siRNA or DMSO did not
affect the plating efficiency of U251MG cells as com-
pared to that of untreated cells (Figure 4A and 4C). In
U343MG cells, a toxic effect of control siRNA was
observed when compared to the untreated cells (reduc-
tion of PE by 40% under normoxia and by 60% under
hypoxia), whereas DMSO did not affect the plating effi-
ciency of U343MG cells (Figure 4B and 4D).
Treatment of U251MG cells with HIF-1a-siRNA
reduced the plating efficiency under normoxic (80%)
(p=0.04) and hypoxic (59%) (p = 0.04) conditions as
compared to that of the control siRNA-treated cells
(Figure 4A). Furthermore, treatment of U343MG cells
with HIF-1a-siRNA decreased the plating efficiency
under normoxic (32%) (p = 0.10, not significant) and
hypoxic (36%) (p=0.05) conditions as compared to that
of the control siRNA-treated cells (Figure 4B).
Treatment of U251MG cells with CTM reduced the
plating efficiencies under normoxic (76%) (p = 0.02) and
hypoxic (75%) (p = 0.07, not significant) conditions as
compared to those the DMSO-treated cells (Figure 4C).
Furthermore, treatment of U343MG cells with CTM
decreased the plating efficiency under normoxic (45%)
(p = 0.0008) and hypoxic (65%) (p = 0.004) conditions as
compared to that of the DMSO-treated cells (Figure 4D).
The clonogenic assay was also applied to determine
whether HIF-1a-siRNA or CTM sensitized glioma cells
U251MG and U343MG to radiation. The viability of
Figure 3 Effects of HIF-1a-siRNA and CTM in U251MG and U343MG Cells: Western Blot Analyses HIF-1a, CAIX and PARP protein
Levels. HIF-1a/CAIX protein expression and PARP cleavage following treatment with 75 nM HIF-1a-siRNA/CTM or 75 nM control siRNA/DMSO in
comparison with untreated cells. Specificity of siRNA on HIF-1a knockdown and effects of CTM on HIF-1 activity under normoxic and hypoxic
conditions. A (U251MG), Treatment with HIF-1a-siRNA caused induction of apoptosis under hypoxic conditions. CAIX expression is inhibited by
HIF-1a silencing under normoxia and hypoxia. B (U343MG), Transfection with HIF-1a-siRNA caused induction of apoptosis under normoxic and
hypoxic conditions. CAIX expression is attenuated by HIF-1a silencing under normoxia and hypoxia. C (U251MG), CTM enhanced the normoxic
and hypoxic HIF-1a protein expression. Treatment with CTM induced apoptosis under normoxic and hypoxic conditions. CTM attenuated the
normoxic and hypoxic CAIX expression. D (U343MG), Treatment with CTM decreased the normoxic and hypoxic HIF-1a protein expression.
Exposure to CTM caused induction of apoptosis under hypoxic conditions. CTM attenuated the normoxic and hypoxic expression of CAIX.
b-Actin served as a loading control.
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U251MG and U343MG cells increased under hypoxic
conditions as compared to normoxia (Figure 5). Survival
curves revealed that, although HIF-1a-siRNA only
slightly diminished the cytotoxic effect of radiation on
U251MG cells under normoxic (DMF10: 0.86, p = 0.04)
conditions, it significantly enhanced radiation sensitivity
of U251MG cells under hypoxic conditions (DMF10:
1.35, p=0.002) (Figure 5A). Further, treatment with
HIF-1a-siRNA resulted in a significantly enhanced
radiosensitivity of U343MG cells under normoxic
(DMF10:1 . 3 3 ,p=0.002) and hypoxic (DMF10: 1.78, p=
0.001) conditions (Figure 5B), respectively.
T h es u r v i v a lc u r v e si n d i c a t et h a te x p o s u r et oC T M
significantly enhanced the effect of radiation in
U251MG cells under normoxic (DMF10: 1.35, p = 0.001)
and hypoxic (DMF10: 1.18, p = 0.04) conditions (Figure
5C). Treatment with CTM did not affect radiosensitivity
of U343MG cells under normoxic (DMF10:1 . 0 2 ,p =
0.01) conditions, but resulted in significant enhanced
Figure 4 Effects of HIF-1a-siRNA or CTM on Clonogenic Survival in U251MG and U343MG Cells (Cytotoxicity). A (U251MG) and B
(U343MG), Effects of treatment with the indicated siRNA (75 nM) on the plating efficiency of non-irradiated cells. C (U251MG) and D
(U343MG), Effects of treatment with 75 nM CTM on the plating efficiency of non-irradiated cells.
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conditions (Figure 5D).
Discussion
In most human cancers including malignant glioma,
HIF-1a expression promotes tumor growth, angiogenesis
and disease progression [18-20]. Additionally, the malig-
nancy of brain tumors is associated with increased intra-
tumoral hypoxia [5].
In the present study, we analyzed the effects of HIF-
1a inhibition by two alternative strategies, siRNA target-
ing of HIF-1a or CTM, on the radioresistance of two
Figure 5 Effects of HIF-1a-siRNA or CTM on Response to Radiation of U251MG and U343MG Cells (Radiosensitivity). A (U251MG) and
B (U343MG), Clonogenic survival following treatment with the indicated siRNA (75 nM) and radiation under normoxia (0-10 Gy) and hypoxia (0-
15 Gy). HIF-1a-siRNA decreased the hypoxia-induced radioresistance of U251MG and U343MG cells. Under normoxia, HIF-1a-siRNA reduces the
response to irradiation in U251MG cells and enhanced the effect of radiation in U343MG cells. C (U251MG) and D (U343MG), Clonogenic
survival following exposure to 75 nM CTM and radiation under normoxia (0-10 Gy) and hypoxia (0-15 Gy). Exposure to CTM decreased hypoxia-
induced radioresistance of U251MG and U343MG cells. CTM enhanced the effect of radiation in U251MG cells and reduced the response to
irradiation in U343MG cells under normoxia.
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U251MG and U343MG displayed comparable HIF-1a
mRNA expression levels under normoxic and hypoxic
conditions. U251MG and U343MG exhibited a weak
HIF-1a protein expression under normoxia with an
increase in HIF-1a protein, CA9 mRNA and CAIX pro-
tein levels under hypoxia. Our previous studies using
the glioma cell line U87MG supported the potential use-
fulness of HIF-1a as an endogenous marker of tumor
hypoxia and of resulting radioresistance of human
tumor cells [21,22]. Furthermore, CAIX was found to be
a suitable marker of current or previous chronic hypoxia
a n dw ep r e v i o u s l yp r o p o s e dt h a tt h ea m o u n to fC A I X -
positive cells in a tumor cell suspension may be related
to the radiosensitivity of this tumor in vivo [23]. Inhibi-
tion of the HIF-1 pathway by siRNA or CTM was per-
formed by quantitative real-time PCR and Western blot
analyses. We showed that HIF-1 targeting via HIF-1a-
siRNA effectively reduced the hypoxia-induced HIF-1a
protein levels of U251MG and U343MG cells. In addi-
tion, exposure to CTM resulted in an increased HIF-1a
protein expression in U251MG cells and decreased
levels of HIF-1a p r o t e i ni nU 3 4 3 M Gc e l l su n d e rn o r -
moxic and hypoxic conditions. CTM is an inhibitor of
the HIF-1a/p300 complex. CTM only interrupts the
transcriptional activity of HIF-1a. Thus, it diminishes
the expression of HIF-1a target genes. U251MG cells
responded as expected because CTM has no influence
on the expression of HIF-1a mRNA. In U251MG cells,
treatment with CTM resulted in a slight increase of
HIF-1a protein stabilisation but attenuated the HIF-1a
induced expression of CAIX. One possible explanation
for the slightly increased HIF-1a p r o t e i ne x p r e s s i o ni n
these cells might be that CTM attenuated the hypoxic
answer. So an auto regulatory feedback loop caused this
stabilisation of HIF-1a. Moreover, another explanation
could be that CTM also inhibits the interaction of HIF-
1a a n dV H L .I nt h i s ,w a ya nu n s p e c i f i cs i d ee f f e c to f
CMT would inhibit the degradation of HIF-1a.
U343MG cell line didn’t respond as expected. In
U343MG cells CTM has an effect on the HIF-1a
expression and on the target gene CAIX. One reason
for that might have been that the applied dose of CTM
in the lower grade 3 glioma cells line U343MG causes
side effects. Further, both cell lines differ in their
genetic status and regulation of different pathways and
consequently in their disease aggressiveness and
response to treatment. Additionally, CTM is a small
molecule and the specificity for the target of small
molecule is debatable and there might be another
mechanism of CTM play a role. Furthermore, our data
indicate that monitoring CA9 mRNA and CAIX protein
expression is a means to verify the inhibition of HIF-1
activity.
Results suggest that inhibition of HIF-1a decreased
tumor growth in malignant gliomas [24]. Additionally,
Dai et al. showed oxygen-independent cytotoxicity and
p53-independent apoptosis by HIF-1a inhibition in glio-
blastoma cells [12]. In the present study, Western blot
analyses of the cleavage of PARP confirm these findings.
Furthermore, treatment of U251MG and U343MG cells
with HIF-1a-siRNA or CTM reduced the plating effi-
ciency under normoxic and hypoxic conditions as com-
pared to that of the control siRNA- or DMSO-treated
cells.
In the literature, hypoxia and HIF-1a-associated resis-
tance to radiotherapy and chemotherapy is discussed.
HIF-1a expression is a significant prognostic indicator
in glial brain tumors treated by radiotherapy [18,25].
Furthermore, HIF-1a exhibits an attractive target to
overcome hypoxia-related radioresistance of tumors
in vitro and in vivo [26]. Silencing of HIF-1a has been
shown to inhibit hypoxia-mediated cell migration and
invasion in in vitro and in vivo malignant glioma mod-
els [13,27,28]. Further, silencing of HIF-1a by siRNA
sensitized glioma cells to the chemotherapeutic agents
doxorubicin and etoposide [14]. This is the first study
showing that inhibition of HIF-1a by siRNA or by
CTM under hypoxic conditions resulted in a signifi-
cantly enhanced radiosensitivity of the human glioma
cells. Recently, HIF-1a inhibition by CTM effectively
reduced hypoxia-dependent transcription and sensitized
hypoxic HT 1080 human fibrosarcoma cells in vitro to
radiation [16].
Although inhibition of HIF-1a under hypoxic condi-
tions enhanced radiosensitivity of glioma cells U251MG
and U343MG, the effects of HIF-1a inhibition on radio-
sensitivity under normoxic conditions were not obvious.
In agreement with our results, Palayoor et al.s h o w e d
that effects of HIF-1a inhibitor PX-478 on radiosensitity
under normoxic conditions were less dramatic than
under hypoxic conditions in prostate carcinoma cells
[29]. Further studies have shown that HIF inhibitors are
more potent in attenuation of HIF-dependent transcrip-
tional activity under hypoxia than under normoxia
[30,31]. Further investigations are necessary to study the
normoxic expression of HIF-1a in malignant glioma cell
lines.
Indeed, siRNA and CTM showed different impacts on
the effects of radiation in the indicated cell lines under
normoxia, as HIF-1a-siRNA reduces the response to
irradiation in U251MG cells, whereas in U343MG cells,
siRNA enhanced the effects of radiation. Furthermore,
under normoxia, CTM enhanced the effects of radiation
in U251MG cells, whereas in U343MG cells, CTM had
no effect on the response to irradiation under normoxia.
The U343MG cell line originated from a de novo grade-
III anaplastic astrocytoma and U251MG was established
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ferent genes involved in cellular pathways regulating
apoptosis, proliferation, and DNA repair could carry
mutations or deletions in these cells. Both cell lines differ
in their genetic status of p53 and consequently in their
disease aggressiveness and response to treatment.
U343MG cells carry wild-type p53, whereas U251MG
carry mutated p53 [32]. Hence, the ability to respond to
radiation may differ in U251MG and U343MG cells.
Additionally, compared to HIF-1a-specific siRNA, CTM
has a different mode of action.
However, the function of CTM is not fully understood.
CTM is a member of the epidithiodiketopiperazine (ETP)
family. Previous studies have shown that ETPs react with
p300 and cause zinc ion ejection. Additionally, the results
of Cook et al. suggest that ETPs also interact with other
zinc ion binding proteins. In addition, it is likely that ETPs
like CTM operate by more than one mechanism in cells
and that CTM had an impact on transcription factors rele-
vant to radiosensitivity [33].
Conclusions
We demonstrate for the first time that both siRNA and
CTM treatment decreased the radioresistance of glioma
cell lines U251MG and U343MG under hypoxic condi-
tions. Further, treatment of glioma cells lines with
siRNA and CTM reduced plating efficiency of these
cells and caused induction of apoptosis under hypoxic
conditions. In conclusion, our results suggest that inhi-
bition of HIF-1a is a promising strategy to reduce cell
survival and to enhance the response of malignant glio-
mas to radiotherapy.
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